膀胱癌组织微RNA-212、微RNA-137、微RNA-200表达与临床病理特征的相关性及预测经尿道膀胱肿瘤切除术后复发的效能研究

Correlation between microRNA-212,microRNA-137 and microRNA-200 expressions and clinicopathological features of bladder cancer tissues and their efficacy in predicting recurrence after transurethral resection of bladder tumors

目的 探讨膀胱癌组织微RNA-212(miRNA-212)、微RNA-137(miRNA-137)、微RNA-200(miRNA-200)表达与临床病理特征的相关性及预测经尿道膀胱肿瘤切除(TURBT)术后复发的效能。方法 选取2017年6月至2021年6月河北燕达医院100例膀胱癌病人,比较癌组织和癌旁组织及不同病理特征病人miRNA-212、miRNA-137、miRNA-200表达,并根据术后复发情况分为复发组、未复发组。比较两组miRNA-212、miRNA-137、miRNA-200表达,采用受试者操作特征(ROC)曲线分析miRNA-212、miRNA-137、miRNA-200预测复发的价值,比较不同miRNA-212、miRNA-137、miRNA-200表达水平病人复发率。结果 癌组织miRNA-212为2.03±0.56低于癌旁组织4.52±1.18(P<0.05),癌组织miRNA-137、miRNA-200表达分别为2.69±0.45、24.56±7.39,高于癌旁组织的1.28±0.30、7.33±2.21(P<0.05);随着组织学分级、TNM分期递增,miRNA-212表达逐渐降低,miRNA-137、miRNA-200表达逐渐升高(P<0.05);肌层浸润性膀胱癌病人miRNA-212低于非肌层浸润性膀胱癌,miRNA-137、miRNA-200高于非肌层浸润性膀胱癌(P<0.05);复发组miRNA-212(1.73±0.39)低于未复发组(2.28±0.44)(P<0.05),复发组miRNA-137、miRNA-200分别为3.06±0.72、37.96±12.18,高于未复发组2.35±0.40、22.86±7.50(P<0.05);miRNA-212高水平病人复发率低于低水平病人,miRNA-137、miRNA-200高水平病人复发率高于低水平病人(P<0.05)。结论 膀胱癌组织miRNA-212、miRNA-137、miRNA-200表达与临床病理特征相关,联合检测对TURBT后复发具有良好的预测能力,可作为预测术后复发的一种方案。

Objective To explore the correlation of microRNA-212(miRNA-212),microRNA-137(miRNA-137),and microRNA-200(miRNA-200)expressions in bladder cancer tissues with clinicopathological features and the efficacy of predicting recurrence after transurethral resection of bladder tumor(TURBT).Methods A total of 100 patients with bladder cancer admitted to Hebei Yanda Hos-pital from June 2017 to June 2021 were randomly selected to compare the expressions of miRNA-212,miRNA-137,and miRNA-200 in cancer tissues,adjacent tissues,and patients with different pathological characteristics.They were assigned into recurrence group and non-recurrence group according to postoperative recurrence.A comparison was made of the expressions of miRNA-212,miRNA-137,and miRNA-200 between the two groups,and the predictive values of miRNA-212,miRNA-137,and miRNA-200 for recurrence were analyzed using receiver operating characteristic curves(ROC).Meanwhile,the recurrence rates of patients with different expression lev-els of miRNA-212,miRNA-137,and miRNA-200 were also compared.Results The expression of miRNA-212 in cancer tissues was 2.03±0.56,which was lower than that in adjacent tissues 4.52±1.18(P<0.05).The expressions of miRNA-137 and miRNA-200 in can-cer tissues were 2.69±0.45 and 24.56±7.39,respectively,which were higher than those in adjacent tissues(1.28±0.30 and 7.33±2.21,P<0.05).As histological grading and TNM staging increased,the expression of miRNA-212 gradually decreased,while the expressions of miRNA-137 and miRNA-200 gradually increased(P<0.05).The miRNA-212 expression of myometrial invasive bladder cancer patients was lower than that of non-myometrial invasive bladder cancer patients,while the expressions of miRNA-137 and miRNA-200 were higher in myometrial invasive bladder cancer patients than those non-myometrial invasive bladder cancer patients(P<0.05).The miR-NA-212 expression in the recurrent group was 1.73±0.39,which was lower than that in the non-recurrent group 2.28±0.44(P<0.05),while the miRNA-137 and miRNA-200 in the recurrent group were 3.06±0.72 and 37.96±12.18,which were higher than those in the non-recurrent group(2.35±0.40 and 22.86±7.50,P<0.05).The recurrence rate of patients with high-level miRNA-212 was lower than that of patients with low-level miRNA-212,while the recurrence rate of patients with high-level miRNA-137 and miRNA-200 was high-er than that of patients with low-level miRNA-137 and miRNA-200(P<0.05).Conclusion The expressions of miRNA-212,miRNA-137 and miRNA-200 in bladder cancer tissues correlate with clinicopathological features,and the combined assay has good predictive ability for recurrence after TURBT,which can be used as a predictive scheme for postoperative recurrence.